CN102772455A - Seabuckthorn flavone dispersible tablets - Google Patents
Seabuckthorn flavone dispersible tablets Download PDFInfo
- Publication number
- CN102772455A CN102772455A CN2012102406379A CN201210240637A CN102772455A CN 102772455 A CN102772455 A CN 102772455A CN 2012102406379 A CN2012102406379 A CN 2012102406379A CN 201210240637 A CN201210240637 A CN 201210240637A CN 102772455 A CN102772455 A CN 102772455A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus hippophae
- flavone
- mixture
- mix homogeneously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses seabuckthorn flavone dispersible tablets, which are prepared by mixing, pelletizing and tabletting 10-25 parts of seabuckthorn flavone, 8-16 parts of disintegrating agent, 30-60 parts of filling agent, 2-8 parts of swelling adjuvants, 1-5 parts of bonding agent, 0.5-1 parts of lubricating agent and 1-3 parts of flavoring agents. Compared with the prior art, the seabuckthorn flavone dispersible tablets provided by the invention are good in taste, short in disintegration time, and is capable of quickly disintegrating within 35-55 seconds, and medicines are dissolved out fast, thereby being capable of being sucked, swallowed, and taken after being added water to disperse. Therefore, the seabuckthorn flavone dispersible tablets are ideal medicinal preparation for preventing and treating cardiovascular and cerebrovascular diseases.
Description
Technical field
The present invention relates to a kind of Fructus Hippophae flavone dispersible tablet.
Background technology
Fructus Hippophae is traditional medication of Mongolian medicine and Tibetan medicine, and it is warm in nature and sour-puckery flavor has the effect of YIN nourishing and the production of body fluid promoting, reinforce functional activities of the heart, strengthening by means of tonics, and the merit of stronger invigorating blood circulation addiction is arranged.Modern pharmacology and clinical confirms that all Fructus Hippophae flavone contained in the Fructus Hippophae has the myocardial flow of increasing, improves myocardium microcirculation, reduces effects such as myocardial oxygen consumption, arrhythmia and blood vessel dilating.Therefore, Fructus Hippophae flavone be used to treat angina pectoris, nervous, cardiopalmus, uncomfortable in chest, the disease such as blood vessels are not smooth of breathing hard.General Fructus Hippophae flavone is the alcohol extract of Fructus Hippophae, and the Fructus Hippophae flavone structure is special, composition is complicated, has isolated nearly ten kinds of compositions such as isorhamnetin, Quercetin, kaempferol, glucoside after deliberation.
With Fructus Hippophae flavone is that the tablet that main composition is processed is claimed " Fructus Hippophae flavone sheet ", is the medicine that the national drug standards " the chemical drugs terrestrial reference rises GB " (the 14) go up promulgation; Its capsule preparations then is called " Fructus Hippophae flavone capsule ".These two kinds of preparations have been widely used in the clinical treatment cardiovascular and cerebrovascular disease.But the drawback of these two kinds of preparations is that the dispersion of Fructus Hippophae flavone wherein is not too high, has delayed the onset time of Fructus Hippophae flavone drug effect, thus a kind of onset the new formulation dosage form is more with practical value faster.
Dispersible tablet means the rapid homodisperse a kind of tablet of disintegrate of ability in water, is a kind of quick-effective preparation that development in recent years is got up, because its distinctive advantage more and more receives people's attention.2000 editions two radicals by which characters are arranged in traditional Chinese dictionaries of Chinese Pharmacopoeia have recorded this dosage form.Below with regard to its performance and characteristics, do a concise and to the point introduction.
(1) compares with conventional tablet
Dispersible tablet has the following advantages:
1, good dispersing state, disintegration time are short, the medicine stripping is rapid;
2, absorption is fast, bioavailability is high;
3, taking convenience can be swallowed, chew to contain and suck or with taking after the aqueous dispersion, especially is fit to old man, paralytic and the patient of the difficulty of swallowing takes;
4, these article are processed dispersible tablet, take onset rapidly at acute attack stages such as coronary heart disease, angina pectoriss, effectively disease controlling.
(2) compare with effervescent tablet, freeze-dried instant sheet
The production technology of dispersible tablet is identical with conventional tablet, does not need gas-producing disintegrant, does not need the gentle relative humidity in control room, does not need vacuum lyophilization and extra package, need not specific (special) requirements, and production cost is low.
(3) compare with drop pill
Dispersible tablet and drop pill are all quick-effective preparation, and dispersible tablet takes that mode is various, and disintegrate is faster, and bioavailability is high, and production equipment is identical with conventional tablet, need not to add again equipment.
(4) compare with soft capsule
Dispersible tablet has the fast advantage of oral absorption in external disintegrate, has production simultaneously, carries, convenient transportation and advantage such as stable.
(5) compare with injection
These article are processed dispersible tablet and are convenient to the patient and take for a long time.
Chinese patent notification number CN10537039A discloses a kind of drop pills of seabuckthorn fruit flavone, still, and the bitter problem of the unresolved Fructus Hippophae flavone mouthfeel of the drops that this method provided.
The Chinese patent notification number is that CN101023969A processes a kind of soft capsule with Fructus Hippophae flavone, and still, the soft capsule dosage form that this method provided can not solve the difficult patient's that swallows medication problem.
The Chinese patent notification number is that CN1981789A processes a kind of micropill with Fructus Hippophae flavone; But the micropill dosage form that this method provided is a kind of slow release formulation, and it can not reach onset purpose rapidly through quick release; Moreover, the problem that also unresolved Fructus Hippophae flavone mouthfeel is bitter.
Summary of the invention
The object of the invention is exactly in order to overcome the shortcoming of existing dosage form, a kind of have good taste and good dispersing state to be provided, the disintegration time weak point; The medicine stripping is rapid; Absorb soon, advantages such as taking convenience can swallow, chew, contain and suck or with the Fructus Hippophae flavone dispersible tablet of taking after the aqueous dispersion; Especially being fit to the old man and the patient of the difficulty of swallowing takes, is first aid, the treatment of clinical cardiovascular and cerebrovascular disease, the active remedy preparation of prevention.
The objective of the invention is to realize like this:
Described Fructus Hippophae flavone dispersible tablet comprises following composition by weight: 10～25 parts of Fructus Hippophae flavones, 8～16 parts of disintegrating agents, 30～60 parts of filleies, 2～8 parts of swellability adjuvants, 1～5 part of binding agent, 0.5～1 part of lubricant, 1～3 part of correctives.
Described disintegrating agent is at least a in crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose and the carboxymethyl starch sodium;
Described filler is at least a in microcrystalline Cellulose, lactose and the mannitol;
Described swellability adjuvant is at least a in sodium alginate, pregelatinized Starch, hydroxypropyl cellulose and the amylum pregelatinisatum;
Described binding agent is at least a in 55%～70% ethanol, 1～3 part of polyvinylpyrrolidone and 97～99 part of 70%～80% alcohol mixed solution, 1～3 part of polyvinylpyrrolidone and 97～99 part of 50%～60% alcohol mixed solution;
Described lubricant is at least a in Pulvis Talci, magnesium stearate and the micropowder silica gel;
Described correctives is at least a in aspartame, stevioside and the acesulfame potassium.
The method for preparing of Fructus Hippophae flavone dispersible tablet of the present invention is following:
Batching: get 2～8 parts of 10～25 parts of Fructus Hippophae flavones, 8～16 parts of disintegrating agents, 30～60 parts of filleies and swellability adjuvants respectively, mix homogeneously;
Granulate: add binding agent and granulate for 1～5 part, process the granule of 0.5～1mm, dry, granulate under 45～55 ℃ condition;
Tabletting: add 1～3 part of 0.5～1 part of lubricant and correctives again, tabletting behind the mix homogeneously is processed the Fructus Hippophae flavone dispersible tablet.
Compared with prior art; Fructus Hippophae flavone dispersible tablet of the present invention is a kind of good taste, disintegrate stripping new formulation rapidly that has, and meets water disintegrate rapidly in 35～55 seconds, its taking convenience; Onset is rapid; Not only can satisfy patient's medication problem of dysphagia, also can satisfy the demand of its medication simultaneously for the anhydrous patient who takes medicine, also overcome other solid dosage forms and do not rectified the insufferable bitterness problem that flavor brings; Having improved patient's compliance, is the clinical desirable active remedy preparation that is used for cardiovascular disease prevention.
The practical implementation instance
Embodiment 1
Get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 38 parts of 10 parts of Fructus Hippophae flavones, 9 parts of crospolyvinylpyrrolidone and lactose, 3 parts of sodium alginates, mix homogeneously; Adding 1 part of 65% ethanol granulates; Process the granule of 0.9mm, dry, granulate under 46 ℃ condition add 2.5 parts of 0.5 part of magnesium stearate and aspartames again; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 2: get an amount of (about about 5 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2065mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 30 parts of 15 parts of Fructus Hippophae flavones, 10 parts of carboxymethyl starch sodium and microcrystalline Cellulose, 5 parts of pregelatinized Starch, mix homogeneously; Add 2 part 70% ethanol, granulate, process the granule of 0.5mm; Dry, granulate under 50 ℃ condition; Add 3 parts of 0.8 part of micropowder silica gel and aspartames again, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 3: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 45 parts in 20 parts of Fructus Hippophae flavones, 13 parts of crospolyvinylpyrrolidone and mannitol, 6 parts of hydroxypropyl celluloses, mix homogeneously; With 2 parts of addings of 70% ethanol, mix homogeneously is granulated; Process the granule of 0.8mm, dry, granulate under 55 ℃ condition add 1.6 parts of 1 part of Pulvis Talci and steviosides again; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 4: get an amount of (about about 4 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 1652mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 21 parts of Fructus Hippophae flavones, 16 parts of cross-linking sodium carboxymethyl celluloses, 55 parts of lactose, 7 parts of amylum pregelatinisatums, mix homogeneously is with the 3 parts of addings of alcoholic acid mixture with 99 part 50% of 1 part of polyvinylpyrrolidone; Mix homogeneously is granulated, and processes the granule of 0.85mm; Dry, granulate under 52 ℃ condition; Add 2 parts of 0.6 part of magnesium stearate and acesulfame potassiums again, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 5: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 24 parts of Fructus Hippophae flavones, two kinds of low-substituted hydroxypropyl cellulose and carboxymethyl starch sodium are in 14 parts in the mixture of 1: 1 ratio, 45 parts of microcrystalline Cellulose; 6 parts of hydroxypropyl celluloses, mix homogeneously is with the 2 parts of addings of alcoholic acid mixture with 98 part 75% of 2 parts of polyvinylpyrrolidones; Mix homogeneously is granulated, and processes the granule of 0.75mm; Dry, granulate under 50 ℃ condition; Add two kinds of 0.6 part of micropowder silica gel and acesulfame potassium and aspartames again in 1.5 parts in the mixture of 2: 1 ratio, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 6: get an amount of (about about 5 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2065mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again three kinds of 12 parts of Fructus Hippophae flavones, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium and cross-linking sodium carboxymethyl celluloses in three kinds of 13 parts in the mixture of 1: 3: 2 ratio and microcrystalline Cellulose, mannitol and lactose in 40 parts in the mixture of 3: 2: 1 ratio; 4 parts of pregelatinized Starch; Mix homogeneously adds 2 part 55% ethanol, mix homogeneously; Granulate; Process the granule of 0.9mm, dry under 45 ℃ condition, granulate, add three kinds of magnesium stearate, micropowder silica gel and Pulvis Talci in three kinds of 0.5 part in the mixture of 2: 1: 1 ratio and aspartame, stevioside and acesulfame potassiums in 1 part in the mixture of 1: 1: 1 ratio; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 7: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again three kinds of 25 parts of Fructus Hippophae flavones, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose in three kinds in 10 parts in the mixture of 2: 1: 1 ratio and lactose, microcrystalline Cellulose, mannitol in 33 parts in the mixture of 5: 2: 1 ratio; 5 parts of sodium alginates; Mix homogeneously adds 4 part 70% ethanol, mix homogeneously; Granulate; Process the granule of 1.0mm, dry under 48 ℃ condition, granulate, add three kinds of micropowder silica gels, magnesium stearate, Pulvis Talci by three kinds of 0.8 part in the mixture of 1: 3: 2 ratio and aspartame, stevioside, acesulfame potassiums in 1 part in the mixture of 1: 4: 2 ratio; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 8: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again 18 parts of Fructus Hippophae flavones, carboxymethyl starch sodium and crospolyvinylpyrrolidone in 9 parts in the mixture of 1: 3 ratio and mannitol, microcrystalline Cellulose and lactose in 40 parts in the mixture of 1: 3: 2 ratio, 6 parts of pregelatinized Starch, mix homogeneously; Add 3 parts of 1 part of polyvinylpyrrolidone and 99 part of 70% alcohol mixed solutions; Mix homogeneously is granulated, and processes the granule of 0.7mm; Dry, granulate under 55 ℃ condition; Add Pulvis Talci and micropowder silica gel again in 1 part in the mixture of 1: 1 ratio and 2.8 parts of steviosides, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 9: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 20 parts of Fructus Hippophae flavones again, with cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, carboxymethyl starch sodium in 2: 1: 1: 8 parts of the mixing of 3 ratio, microcrystalline Cellulose and mannitol are in 50 parts in the mixture of 3: 1 ratio; 7 parts of hydroxypropyl celluloses, remix is even, gets 2 parts of polyvinylpyrrolidones and 4 parts of addings of alcoholic acid mixture of 98 part 80%; Mix homogeneously is granulated, and processes the granule of 0.85mm; Dry, granulate under 52 ℃ of conditions; Add 1.3 parts of 0.6 part of magnesium stearate and acesulfame potassiums again, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 10: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get two kinds of 14 parts of Fructus Hippophae flavones, cross-linking sodium carboxymethyl cellulose and crospolyvinylpyrrolidone in 9 parts in the mixture of 1: 1 ratio and 50 parts of microcrystalline Cellulose, 6 parts of amylum pregelatinisatums, remix is even; Get 2 parts of polyvinylpyrrolidones and 2 parts of addings of alcoholic acid mixture of 98 part 60%; Mix homogeneously is granulated, and processes the granule of 0.75mm; Dry, granulate under 50 ℃ of conditions; Add two kinds of magnesium stearate and micropowder silica gels again in 0.6 part in the mixture of 1: 3 ratio and 1.1 parts of acesulfame potassiums, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 11: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get three kinds of 13 parts of Fructus Hippophae flavones, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium and cross-linking sodium carboxymethyl celluloses again in 10 parts in the mixture of 1: 3: 2 ratio and 60 parts of microcrystalline Cellulose, 5 parts of hydroxypropyl celluloses, remix is even; Add 1 part 65% ethanol; Mix homogeneously is granulated, and processes the granule of 0.6mm; Dry, granulate under 46 ℃ condition; Add again micropowder silica gel and Pulvis Talci in 0.5 part in the mixture of 2: 1 ratio and aspartame, stevioside in 1 part in the mixture of 1: 1 ratio, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 12: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again 25 parts of Fructus Hippophae flavones, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone in 13 parts in the mixture of 1: 4 ratio and lactose, microcrystalline Cellulose in 33 parts in the mixture of 1: 3 ratio, 8 parts of sodium alginates, remix is even; Add 2 part 70% ethanol; Mix homogeneously is granulated, and processes the granule of 0.5mm; Dry, granulate under 45 ℃ condition; Add again micropowder silica gel, Pulvis Talci in 0.8 part in the mixture of 1: 3 ratio and stevioside, acesulfame potassium in 2.6 parts in the mixture of 3: 1 ratio, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 13: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again 23 parts of Fructus Hippophae flavones, carboxymethyl starch sodium and crospolyvinylpyrrolidone in 9 parts in the mixture of 1: 3 ratio and mannitol, microcrystalline Cellulose and lactose in 40 parts in the mixture of 1: 3: 2 ratio, 6 parts of hydroxypropyl celluloses, remix is even; Get 3 parts of polyvinylpyrrolidones and 3 parts of addings of alcoholic acid mixture of 97 part 50%; Mix homogeneously is granulated, and processes the granule of 0.8mm; Dry, granulate under 50 ℃ condition; Add again micropowder silica gel get 1 part with 2 parts of steviosides, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 14: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 21 parts of Fructus Hippophae flavones, cross-linking sodium carboxymethyl cellulose and carboxymethyl starch sodium again in 11 parts in the mixture of 1: 2 ratio and 55 parts of microcrystalline Cellulose, 3 parts of pregelatinized Starch, remix is even; Get 1 part of polyvinylpyrrolidone and 3 parts of addings of alcoholic acid mixture of 99 part 55%, mix homogeneously is granulated; Process the granule of 0.95mm, dry, granulate under 50 ℃ condition add 3 parts of 0.6 part of Pulvis Talci and acesulfame potassiums again; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 15: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again 17 parts of Fructus Hippophae flavones, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium and cross-linking sodium carboxymethyl cellulose in 12 parts in the mixture of 1: 2: 2 ratio and microcrystalline Cellulose and lactose in 40 parts in the mixture of 3: 2 ratio, 8 parts of amylum pregelatinisatums, mix homogeneously; Get 2 parts of polyvinylpyrrolidones and 2 parts of addings of alcoholic acid mixture of 98 part 55%; Mix homogeneously is granulated, and processes the granule of 0.75mm; Dry, granulate under 50 ℃ condition; Add 0.5 part of Pulvis Talci and aspartame, stevioside again in 1 part in the mixture of 1: 1 ratio, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 16: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 50 parts of 15 parts of Fructus Hippophae flavones, 15 parts of low-substituted hydroxypropyl celluloses and microcrystalline Cellulose again, 8 parts of hydroxypropyl celluloses, mix homogeneously; Add 1 part 65% ethanol, granulate, process the granule of 0.55mm; Dry, granulate under 53 ℃ condition; Add 2 parts of 0.8 part of magnesium stearate and aspartames again, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 17: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 60 parts of 13 parts of Fructus Hippophae flavones, 16 parts of crospolyvinylpyrrolidone and lactose again, 8 parts of pregelatinized Starch, mix homogeneously; Add 2 part 70% ethanol, mix homogeneously is granulated; Process the granule of 0.6mm, dry, granulate under 45 ℃ condition add 3 parts of 0.6 part of micropowder silica gel and aspartames again; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 18: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 55 parts in 9 parts of Fructus Hippophae flavones, 11 parts of carboxymethyl starch sodium and mannitol again, mix homogeneously is got 1 part of polyvinylpyrrolidone and 2 parts of addings of alcoholic acid mixture of 99 part 70%; Mix homogeneously is granulated, and processes the granule of 0.8mm; Dry, granulate under 55 ℃ condition; Add 2 parts of 0.6 part of Pulvis Talci and aspartames again, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 19: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 60 parts of 28 parts of Fructus Hippophae flavones, 10 parts of cross-linking sodium carboxymethyl celluloses and microcrystalline Cellulose again, 5 parts of amylum pregelatinisatums, mix homogeneously; Get 2 parts of polyvinylpyrrolidones and 2 parts of addings of alcoholic acid mixture of 98 part 80%, mix homogeneously is granulated; Process the granule of 0.65mm, dry, granulate under 48 ℃ condition add 3 parts of 0.6 part of magnesium stearate and acesulfame potassiums again; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 20: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get two kinds of 17 parts of Fructus Hippophae flavones, cross-linking sodium carboxymethyl cellulose and crospolyvinylpyrrolidone again in 8 parts in the mixture of 3: 1 ratio and 50 parts of microcrystalline Cellulose; Remix is even, gets 3 parts of polyvinylpyrrolidones and 2 parts of addings of alcoholic acid mixture of 97 part 80%, mix homogeneously; Granulate; Process the granule of 0.8mm, dry under 50 ℃ condition, granulate, add again two kinds of magnesium stearate and micropowder silica gels in two kinds of 0.6 part in the mixture of 1: 2 ratio and acesulfame potassium and aspartames in 2 parts in the mixture of 1: 1 ratio; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 21: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again three kinds of 24 parts of Fructus Hippophae flavones, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium and cross-linking sodium carboxymethyl celluloses in three kinds of 14 parts in the mixture of 1: 2: 2 ratio and microcrystalline Cellulose, mannitol and lactose in 40 parts in the mixture of 3: 1: 1 ratio; 6 parts of hydroxypropyl celluloses; Mix homogeneously adds 1 part 65% ethanol, mix homogeneously; Granulate; Process the granule of 0.7mm, dry under 50 ℃ condition, granulate, add again three kinds of magnesium stearate, micropowder silica gel and Pulvis Talci in three kinds of 0.5 part in the mixture of 2: 2: 1 ratio and aspartame, stevioside and acesulfame potassiums in 1 part in the mixture of 1: 3: 1 ratio; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 22: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again three kinds of 18 parts of Fructus Hippophae flavones, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone and cross-linking sodium carboxymethyl celluloses in 12 parts in the mixture of 1: 1: 2 ratio and lactose, microcrystalline Cellulose, mannitol in 35 parts in the mixture of 3: 2: 1 ratio; 7 parts of pregelatinized Starch; Mix homogeneously adds 2 part 70% ethanol, mix homogeneously; Granulate; Process the granule of 0.5mm, dry under 45 ℃ condition, granulate, add again micropowder silica gel, magnesium stearate, Pulvis Talci in three kinds of 0.6 part in the mixture of 1: 2: 3 ratio and aspartame, stevioside, acesulfame potassiums in 1 part in the mixture of 2: 1: 3 ratio; Mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 23: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get again 14 parts of Fructus Hippophae flavones, carboxymethyl starch sodium and super carboxymethyl starch sodium in 8 parts in the mixture of 1: 1 ratio and mannitol, microcrystalline Cellulose and lactose in 56 parts in the mixture of 1: 1: 3 ratio, 3 parts of pregelatinized Starch, remix is even; Add 1 part of polyvinylpyrrolidone and 99 part of 70% alcohol mixed solution; Mix homogeneously is granulated, and processes the granule of 0.8mm; Dry, granulate under 55 ℃ condition; Add Pulvis Talci and micropowder silica gel again in 1 part in the mixture of 1: 1 ratio and 2 parts of steviosides, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 24: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get 11 parts of Fructus Hippophae flavones, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, carboxymethyl starch sodium again in 1: 1: 1: 15 parts in the mixture of 1 ratio and microcrystalline Cellulose and mannitol are in 45 parts in the mixture of 1: 3 ratio; 4 parts of hydroxypropyl celluloses, remix is even, gets 2 parts of polyvinylpyrrolidones and 2 parts of addings of alcoholic acid mixture of 98 part 80%; Mix homogeneously; 5 parts of amylum pregelatinisatums are granulated, and process the granule of 0.85mm; Dry, granulate under 54 ℃ condition; Add 0.6 part of magnesium stearate and acesulfame potassium and aspartame again in 2 parts in the mixture of 1: 3 ratio, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 25: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get two kinds of 17 parts of Fructus Hippophae flavones, cross-linking sodium carboxymethyl cellulose and carboxymethyl starch sodium in 10 parts in the mixture of 1: 2 ratio and 53 parts of lactose, 3 parts of hydroxypropyl celluloses, mix homogeneously; Get 2 parts of polyvinylpyrrolidones and 3 parts of addings of alcoholic acid mixture of 98 part 60%; Mix homogeneously is granulated, and processes the granule of 0.55mm; Dry, granulate under 51 ℃ condition; Add two kinds of magnesium stearate and micropowder silica gels again in 0.6 part in the mixture of 2: 3 ratio and 2 parts of acesulfame potassiums, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Embodiment 26: get an amount of (about about 6 grams) Fructus Hippophae flavone, detecting the active ingredient " flavone " that shows wherein, to be equivalent to isorhamnetin, kaempferol, Quercetin total content be 2478mg, grinds the back and cross 100 mesh sieves, subsequent use.Get three kinds of 10 parts of Fructus Hippophae flavones, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium and cross-linking sodium carboxymethyl celluloses again in 13 parts in the mixture of 2: 3: 1 ratio and 50 parts of microcrystalline Cellulose, 8 parts of sodium alginates, remix is even; Add 1 part 65% ethanol; Mix homogeneously is granulated, and processes the granule of 0.7mm; Dry, granulate under 50 ℃ condition; Add again micropowder silica gel and Pulvis Talci in 0.5 part in the mixture of 1: 1 ratio and aspartame, stevioside in 1 part in the mixture of 1: 3 ratio, mixing, tabletting promptly make Fructus Hippophae flavone dispersible tablet of the present invention.
Claims (1)
1. Fructus Hippophae flavone dispersible tablet is characterized in that:
Batching: get 10～25 parts of Fructus Hippophae flavones, 8～16 parts of disintegrating agents, 30～60 parts of filleies, 2～8 parts of mix homogeneously of swellability adjuvant;
Granulate: add binding agent and granulate for 1～5 part, process the granule of 0.5～1mm, dry, granulate under 45～55 ℃ condition;
Tabletting: add 0.5～1 part of lubricant, tabletting behind 1～3 part of mix homogeneously of correctives is processed the Fructus Hippophae flavone dispersible tablet;
Described disintegrating agent is at least a in crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose and the carboxymethyl starch sodium;
Described filler is at least a in microcrystalline Cellulose, lactose, the mannitol;
Described swellability adjuvant is at least a in sodium alginate, pregelatinized Starch, hydroxypropyl cellulose and the amylum pregelatinisatum;
Described binding agent is at least a in 55%～70% ethanol, 1～3 part of polyvinylpyrrolidone and 97～99 part of 70%～80% alcohol mixed solution, 1～3 part of polyvinylpyrrolidone and 97～99 part of 50%～60% alcohol mixed solution;
Described lubricant is at least a in Pulvis Talci, magnesium stearate, the micropowder silica gel;
Described correctives is at least a in aspartame, stevioside, the acesulfame potassium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102406379A CN102772455A (en) | 2012-07-10 | 2012-07-10 | Seabuckthorn flavone dispersible tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102406379A CN102772455A (en) | 2012-07-10 | 2012-07-10 | Seabuckthorn flavone dispersible tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102772455A true CN102772455A (en) | 2012-11-14 |
Family
ID=47117712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102406379A Pending CN102772455A (en) | 2012-07-10 | 2012-07-10 | Seabuckthorn flavone dispersible tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102772455A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103690576A (en) * | 2013-12-16 | 2014-04-02 | 小金县四姑娘山天然沙棘食品有限公司 | High-seabuckthorn Vc sugar-free lozenge and preparation method thereof |
| CN106074681A (en) * | 2016-06-17 | 2016-11-09 | 中国人民解放军第四军医大学 | A kind of dispersible tablets of Chinese medicine of anti-hepatic fibrosis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833639A (en) * | 2006-01-11 | 2006-09-20 | 北京因科瑞斯生物制品研究所 | 'Xindakang' dispersion tablets and prepn. method |
| CN1857342A (en) * | 2006-03-30 | 2006-11-08 | 陕西海天制药有限公司 | Seabuckthorn preparation and its preparing process |
-
2012
- 2012-07-10 CN CN2012102406379A patent/CN102772455A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833639A (en) * | 2006-01-11 | 2006-09-20 | 北京因科瑞斯生物制品研究所 | 'Xindakang' dispersion tablets and prepn. method |
| CN1857342A (en) * | 2006-03-30 | 2006-11-08 | 陕西海天制药有限公司 | Seabuckthorn preparation and its preparing process |
Non-Patent Citations (2)
| Title |
|---|
| 党学良等: "芪天分散片的成型工艺研究", 《华西药学杂志》 * |
| 邹珊珊等: "醋柳黄酮及其制剂研究概述", 《中国药师》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103690576A (en) * | 2013-12-16 | 2014-04-02 | 小金县四姑娘山天然沙棘食品有限公司 | High-seabuckthorn Vc sugar-free lozenge and preparation method thereof |
| CN103690576B (en) * | 2013-12-16 | 2015-12-09 | 小金县四姑娘山天然沙棘食品有限公司 | High Fructus Hippophae Vc sugar-free buccal tablet and preparation method thereof |
| CN106074681A (en) * | 2016-06-17 | 2016-11-09 | 中国人民解放军第四军医大学 | A kind of dispersible tablets of Chinese medicine of anti-hepatic fibrosis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101099729B (en) | Oral solid preparation containing ambroxol hydrochloride and salbutamol active components | |
| KR101435229B1 (en) | Orally disintegrating tablet and process for production thereof | |
| CN101888834A (en) | Oral dispersable tablet | |
| RU2583935C2 (en) | Pharmaceutical composition for oral administration with masked taste and preparation method thereof | |
| WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
| CN102355890A (en) | Orally disintegrating tablet | |
| JP2008285434A (en) | Quickly disintegrating tablet in oral cavity | |
| CN100546571C (en) | Sangju effervescent tablet for treating common cold | |
| CN101461788B (en) | Phloroglucine orally disintegrating tablet and preparation method thereof | |
| CN102631329A (en) | Oral paroxetine disintegrating tablet and preparation process thereof | |
| CN103120652B (en) | Phloroglucin orally disintegrating tablet and preparation method thereof | |
| JP6479658B2 (en) | Super-fast disintegrating tablet and method for producing the same | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN102772455A (en) | Seabuckthorn flavone dispersible tablets | |
| CN102872024B (en) | Misoprostol medicine combination used in mouths | |
| US20110091536A1 (en) | Compositions comprising euphorbia prostrata and process of preparation thereof | |
| JP2019131597A (en) | Super quick decomposition tablet and production method thereof | |
| JP6469234B2 (en) | Super-fast disintegrating tablet and method for producing the same | |
| TWI644688B (en) | Method for producing orally disintegrating lozenge containing disintegrating particle composition | |
| CN100536829C (en) | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method | |
| CN101152187A (en) | Eplerenone pharmaceutical composition | |
| CN1321645C (en) | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor | |
| CN102048810B (en) | Dracocephalum moldavica general flavone orally disintegrating tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121114 |